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Introduction
Acetylsalicylic acid is one of the most widely used drug as an anti-
inflammatory, analgesic, and antipyretic drug. Moreover, in low-dose it 
is also used as antithrombotic agent to inhibit cyclooxygenase-dependent 
platelet aggregation responsible for the formation of thrombi, which 
may be related to myocardial infarction and stroke [1-3]. 
Acetylsalicylic acid also inhibits Cyclooxygenase (COX) in the 
Gastrointestinal (GI) tract, which may lead to significant side effects 
including dyspeptic symptoms, peptic ulcers, as well as serious upper GI 
ulcer-related complications such as peptic ulcer bleeding or perforation, 
even when acetylsalicylic acid is given at low doses [4-6]. Enteric-
coated formulations are widely used to minimize the GI side effects of 
acetylsalicylic acid and have been shown to reduce, at least partially, 
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Abstract
Introduction: Low-dose acetylsalicylic acid is used as antithrombotic agent and the enteric-coated formulations 
are widely used to minimize the gastrointestinal side effects. 
Aim: To compare the bioavailability of two acetylsalicylic acid formulations (Ecasil-81®, 81 mg coated tablet) in 
fasting healthy volunteers.
Methods: Healthy volunteers (n=16) were recruited to a monocentric, open label, randomized, two-way 
crossover pharmacokinetic study, with seven days washout period between the treatments. They received a single 
81 mg oral dose of a test (new formulation) or a standard reference formulation of acetylsalicylic acid (Ecasil-81®) 
after about 8 h fasting. Blood samples were collected over a period of 36 h. The salicylic acid plasma concentration 
was evaluated by high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). 
Noncompartmental pharmacokinetic analysis was performed using the WinNonlin program.
Results: The maximum plasma concentration (Cmax) of salicylic acid was 5433 and 5719 ng/mL reached in 3.66 
and 4.02 h (tmax) for the test and the reference formulation, respectively. The 90% confidence interval of the ratios of 
geometric means of Cmax and area under curve of plasma concentration until the last concentration observed (AUC0-
last) were within the interval 80-125%. 
Conclusion: The new acetylsalicylic acid formulation has a bioavailability equivalent to the reference formulation 
for the rate and the extent of absorption.
these GI toxicity [7,8]. Regarding the anti-platelet effects, some studies 
suggest the enteric-coated formulations may be less bioavailable and 
might decrease the anti-thrombotic activity, mainly at low doses [9-
11]. However, an enteric-coated, low-dose (81 mg acetylsalicylic acid) 
study reported that the anti-platelet effects are not adversely affected by 
enteric coating [12]. 
After oral administration, acetylsalicylic acid is well absorbed in the 
gastrointestinal tract and quickly hydrolyzed to form salicylic acid, the 
primarily responsible for the pharmacological effect of acetylsalicylic 
acid. Further, salicylic acid is metabolized to salicyluric acid, gentisic 
acid and other conjugates or the compound can be directly excreted 
[13,14]. The maximum plasma concentration (Cmax) was 170 ng/mL 
reached in 3.25 (tmax) for acetylsalicylic acid and 3780 ng/mL with tmax 
of 4.75 h for salicylic acid. Their elimination half-life (t1/2) was 0.65 
and 2.04 h for acetylsalicylic acid and salicylic acid, respectively, after 
a single oral dose administration of an enteric-coated pellets 100 mg 
acetylsalicylic acid in healthy volunteers [2]. 
*Corresponding author: De Nucci G, State University of Campinas (UNICAMP), 
Faculty of Medical Sciences, Department of Pharmacology, Alexander Fleming 
Street, 105, 13083-881, Campinas, SP, Brazil, Tel: 55-19-3251-6928; Fax: 55-19-
3252-1516; E-mail: denucci@gilbertodenucci.com
Received July 12, 2017; Accepted July 20, 2017; Published July 31, 2017
Citation: Dolores RC, Antunes NJ, Moreno R, Di Vaio P, Magli E, et al. (2017) 
Comparative Bioavailability Study of Two 81 mg Coated Tablet Formulations of 
Acetylsalicylic Acid in Fasting Healthy Volunteers. J Bioequiv Availab 9: 477-483. 
doi: 10.4172/jbb.1000348
Copyright: © 2017 Dolores RC, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited.
Citation: Dolores RC, Antunes NJ, Moreno R, Di Vaio P, Magli E, et al. (2017) Comparative Bioavailability Study of Two 81 mg Coated Tablet 
Formulations of Acetylsalicylic Acid in Fasting Healthy Volunteers. J Bioequiv Availab 9: 477-483. doi: 10.4172/jbb.1000348
J Bioequiv Availab, an open access journal
ISSN: 0975-0851 Volume 9(5): 477-483 (2017) - 478 
This study aims to compare the bioavailability of two acetylsalicylic 
acid formulations (Ecasil-81®, 81 mg coated tablet) in fasting healthy 
volunteers after a single oral dose administration. Considering 
that acetylsalicylic acid is rapidly converted to salicylic acid and it 
is the primarily responsible for the pharmacological effect of the 
parent drug, the acetylsalicylic acid formulations bioavailability was 
investigated through the salicylic acid measurement in plasma using 
high-performance liquid chromatography coupled to tandem mass 
spectrometry (HPLC-MS/MS).
Materials and Methods
Clinical protocol
Sixteen healthy volunteers of both sexes (8 female and 8 male) aged 
between 18 and 55 years old and not obese (Table 1) were included in 
this study. They had liver, kidney and cardiac function within normal 
limits previously accessed by clinical evaluation (medical history, 
physical examination and ECG) and the laboratory tests (haemoglobin, 
haematocrit, total and differential white cell counts, blood glucose, 
urea, creatinine, aspartate aminotransferase, alanine aminotransferase, 
alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, 
albumin, total protein, triglyceride, total cholesterol, uric acid, routine 
urinalysis and proto-parasitological). All subjects were negative for HIV, 
HCV, HBsAg and Anti-HBc. All female subjects were negative for the 
beta human chorionic gonadotropin test. One volunteer dropped out 
of the study for personal reasons. The study was approved by the local 
Research Ethics Committee (protocol GDN 014/15) and the subjects 
signed the informed consent. The study was performed according to the 
2008 revised Declaration of Helsinki for biomedical research involving 
human subject.
This study was performed with a monocentric, open label, 
randomized, two-way crossover pharmacokinetic study, with seven 
days washout period between the treatments. The healthy volunteers 
were hospitalized and received a single oral 81 mg dose of a test (new 
formulation) or standard reference formulation of acetylsalicylic acid 
(Ecasil-81 Biolab Sanus Farmacêutica, Brazil) with 200 mL of water 
after an overnight fast (approximately 8 h). Blood samples (7 mL) were 
collected via a venous catheter into heparinized tubes at times zero, 
0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.33, 2.67, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 
12, 16, 24 and 36 h after drug administration.
The plasma samples for chromatographic analysis were obtained by 
centrifugation (2000 g × 10 min) of the blood samples. Plasma samples 
were stored at -70°C until the time analysis.
The safety assessment was based on recording adverse events 
throughout the study duration. The subject’s systolic and diastolic 
pressures, heart rate and temperature were determined prior and at 
approximately 4, 8, 12 and 24 h after drug administration. The clinical 
evaluation and the laboratory tests were also performed at the end of 
the study.
Analytical assays
Chemicals and reagents: Salicylic acid was purchased from the 
United States Pharmacopeia (Rockville, MD, USA), and salicylic 
acid-d4 was purchased from Toronto Research Chemicals (North York, 
Canada). Acetonitrile and methanol (HPLC grade) were purchased 
from J.T. Baker (Phillipsburg, NJ, USA); ammonium acetate, acetic 
acid, ethanol and dichloromethane (analysis grade) from J.T. Baker 
(Ecatepec, Mexico). The water was obtained from the purification 
system Synergy UV® (Millipore, Molsheim, France).
Calibration standards and quality controls
Stock solutions of salicylic acid and salicylic acid-d4 (IS: Internal 
Standard) were prepared in methanol/water (50/50, v/v). Calibration 
curves for salicylic acid were prepared by adding salicylic acid to blank 
plasma to yield final concentrations of 50, 100, 200, 500, 1000, 1800, 2800 
and 4000 ng/mL. The calibration curves were performed in duplicate for 
each day’s assays. The Quality Control (QC) samples were prepared in 
blank plasma at low, middle 1, middle 2 and high concentrations of 80, 
160, 1600, and 3200 ng/mL, respectively. The dilution QC was prepared 
in blank plasma at 6400 ng/mL.
Sample preparation
Aliquots of 100 μL of plasma were added to glass tubes and spiked 
with 50 µL of IS solution (salicylic acid-d4 5000 ng/mL). The tubes were 
vortexed for 5 s and 10 μL of formic acid 88% were added. The samples 
were vortexed for 5 s again. Three mL of ether/dichloromethane (60/40, 
v/v) were added and the samples were vortexed for 50 s. The samples 
were frozen at -80ºC and the organic phase transferred to another tube 
in which the organic solvents were evaporated under N2 flow at 45ºC. 
The dry residues were dissolved in 200 μL of methanol/water (50/50, 
v/v)+20 nM ammonium acetate, vortexed for 10 s and transferred to 
microvials for analysis.
Liquid chromatography
An aliquot (15 μL) of each plasma extracted was injected into a 
150 × 4.6 mm Inertsil ODS-3 column. The temperature of column was 
maintained constant at 60°C. The mobile phase used was methanol/
water (50/50, v/v)+20 nM ammonium acetate at a flow rate of 900 μL/
min. The temperature of the auto-sampler was maintained at 25°C.
Mass spectrometry
A Quattro Micro mass spectrometer (Micromass, Manchester, UK) 
equipped with an electrospray interface operating in negative ion mode 
was configured for Multiple Reaction Monitoring (MRM) to monitor 
the transitions 137.00>93.00 and 141.30>97.20 for salicylic acid and 
salicylic acid-d4, respectively. The ion-spray capillary voltage was set at 
-2.8 kV. The voltage of the cone was kept at -35 V for salicylic acid and 
-25 V for salicylic acid-d4. The collision energy was -20 eV for salicylic 
acid and salicylic acid-d4. The data acquisition and quantification 
were performed using MassLynx version 4.0 software (Micromass, 
Manchester, UK).
Method validation
The method validation was carried out according to the United States 
Food and Drug Administration (FDA) bioanalytical method validation 
guidance [15] and the Brazilian National Sanitary Surveillance Agency 
(ANVISA) [16]. To evaluate the specificity of the method, eight different 
blank plasma lots (4 normal, 2 hemolyzed and 2 lipemic plasmas) were 
tested for its interferences using the proposed extraction procedure 
and the chromatographic or spectroscopic conditions and compared 
with those obtained in the samples processed from the Lower Limit 
Variable Healthy volunteers
Age (years) 31.0 (18.0-51.0)
Weight (kg) 71.0 (51.0-86.0)
High (m) 1.68 (1.55-1.75)
Body mass index (kg/m2) 25.28 (21.23-28.73)
Gender (Male/Female) 8/7
Table 1: Demographic data of the healthy volunteers (n=15).
Citation: Dolores RC, Antunes NJ, Moreno R, Di Vaio P, Magli E, et al. (2017) Comparative Bioavailability Study of Two 81 mg Coated Tablet 
Formulations of Acetylsalicylic Acid in Fasting Healthy Volunteers. J Bioequiv Availab 9: 477-483. doi: 10.4172/jbb.1000348
J Bioequiv Availab, an open access journal
ISSN: 0975-0851 Volume 9(5): 477-483 (2017) - 479 
of Quantification (LLOQ). The calibration curves were prepared by 
assaying standard plasma samples at eight concentrations of salicylic 
acid (50-4000 ng/mL) in triplicate and the linearity of each calibration 
curve was determined by plotting the peak area ratio (y) of salicylic 
acid/internal standard vs. nominal concentration of analyte. The 
calibration curve was constructed by weighted (1/x) least squares linear 
regression. The accuracy and precision of assay were evaluated by intra- 
and inter-assay studies. Seven aliquots of each QC plasma samples (80, 
160, 1600, 3200 and 6400 ng/mL) were run in three validation batches 
on three different days. Inter and intra-day precisions were determined 
as coefficient of variation, CV (%)=(SD/M) × 100 and the accuracy as the 
percentage relative error, RE (%)=[(E-T)/T] × 100, where M is the mean, 
SD is the standard deviation of M, E is the experimentally determined 
concentration and T is the theoretical concentration. The matrix effect 
experiments were performed using the ratio between salicylic acid (80 and 
3200 ng/mL) and IS injected directly into the mobile phase and standard 
solutions added to blank plasma extracts (4 normal, 2 hemolyzed and 2 
lipemic plasmas). Each sample was obtained by a matrix factor normalized 
by IS (MFN) according to the following formula: MFN=(response of the 
analyte in matrix/internal standard response matrix)/(response of the 
analyte in solution/response of the internal standard solution). Stability 
QC plasma samples (80 and 3200 ng/mL) were subjected to short-term (6 
h 24 min) room temperature, three freezes-thaw (-20-25°C) cycles and 44 
h 40 min autosampler (25ºC) stability tests in triplicate. The stability results 
were compared with the nominal value.
Pharmacokinetic and statistical analysis
Pharmacokinetic analysis was performed using the WinNonlin 
software, version 5.0 (Pharsight Corp, Mountain View, CA, USA). 
The pharmacokinetic parameters were calculated based on the plasma 
concentrations obtained experimentally using a non-compartmental 
model. 
Statistical analysis was performed based on a multivariate model 
for values of area under curve of plasma concentration (AUC) and 
Cmax using Graph Pad Prism Version 3.02 software. The design was 
evaluated using an appropriate model (Mixed Models Procedure), 
having the treatment as fixed effect and the subjects as a random effect. 
The comparative bioavailability mean evaluation was performed by the 
geometric mean of the confidence interval, using two-tailed tests. The 
established criteria for all the parameters were 90% confidence interval 
within the range of 80-125%.
Results and Discussion
The healthy volunteers included in the study (n=15) well tolerated 
the clinical protocol and reported no clinically significant adverse 
effects. Only eight subjects reported headache, which was considered 
probably not related to the administration of acetylsalicylic acid. The 
clinical evaluation, the monitoring of vital signs and laboratory tests 
presented no clinically relevant alterations after acetylsalicylic acid 
administration.
The method for analysis of salicylic acid was developed using the 
HPLC-MS/MS system and a liquid-liquid extraction. The salicylic 
acid was separated on a Inertsil ODS-3 column, with a mobile phase 
consisting of methanol/water (50/50, v/v)+20 nM ammonium acetate. 
The retention time of salicylic acid and IS was 2.36 ± 0.3 and 2.32 ± 
0.3, respectively, and the total run time was 3.7 min. The spectrum for 
compounds showed base peak ions ([M+H]-) at mass-to-charge ratio 
(m/z) of 137.30 for salicylic acid and 141.36 for salicylic acid-d4 (Figure 
1A and 1C). The product ion scan showed that m/z 93.18 and 97.06 
were the most abundant product ions for salicylic acid (Figure 1B) and 
salicylic acid-d4 (Figure 1D). Figure 2 exhibits the chromatograms of 
blank human plasma (Figure 2A), human plasma spiked with 1000 
ng/mL salicylic acid and 5000 ng/mL salicylic acid-d4 (Figure 2B), 
Figure 1: (A) Mass spectrum of the protonated molecular ion of salicylic acid-m/z=137.30; (B) Ion product of salicylic acid-m/z=93.18; (C) Protonated molecular 
ion of salicylic acid-d4-m/z=141.36; and (D) The ion product of salicylic acid-d4-m/z=97.06.
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A
B
C
Figure 2: Chromatograms obtained in the analysis of salicylic acid in plasma. (A) Blank human plasma; (B) Blank plasma spiked with salicylic acid (1000 ng/mL) 
and salicylic acid-d4 (5000 ng/mL); and (C) Plasma of a healthy volunteer obtained 3.30 h after oral dose administration test formulation of 81 mg salicylic acid.
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Parameter
Salicylic acid (ng/mL)
LLOQ
(50)
QC
(80) QC (160) QC (1600) QC (3200)
QC
(6400-1:2)
Intra-batch
Mean (n=7) 51.9 80.1 160.0 1620.0 3240.0 3300.0
Precision (CV %) 5.8 4.1 1.0 1.0 1.5 1.3
Accuracy (%) 103.8 100.1 101.1 101.4 101.2 103.1
Inter-batch
Mean (n=21) 52.2 84.7 168.5 1599.9 3179.6 3210.5
Precision (CV %) 7.5 5.9 4.7 2.2 3.5 4.9
Accuracy (%) 104.4 105.9 105.3 100.0 100.1 100.3
CV%=[(SD/M) × 100]; Accuracy%=[(E−T)/T] × 100; CV: Coefficient of Variation; M: Mean; SD: Standard Deviation of M; E: Experimentally Determined Concentration; T: 
Theoretical Concentration; LLOQ: Lower Limit of Quantification; QC: Quality Control
Table 2: Precision and accuracy data from salicylic acid validation in human plasma.
Salicylic acid FMN CV (%)
80 ng/mL 0.027 2.6
3200 ng/mL 1.017 1.0
FMN: Matrix factor normalized by internal standard [(response of the analyte in matrix/internal standard response matrix)/(response of the analyte in solution/response of 
the internal standard solution)]. CV: Coefficient of Variation [(standard deviation FMN/mean FMN) × 100]
Table 3: Matrix effect for salicylic acid and Internal Standard (IS) in eight different lots of human plasma: 4 normal, 2 lipemic and 2 hemolysate plasmas.
Stability Mean (ng/mL) CV (%) Accuracy (%)
Short term (4 h)
80 ng/mL 76.2 5.0 95.3
3200 ng/mL 3050 1.9 95.3
Freeze/thaw (3 cycles)
80 ng/mL 78.1 2.1 97.6
3200 ng/mL 3050 1.0 95.3
Post-processing (24 h)
80 ng/mL 77.1 4.1 96.4
3200 ng/mL 3070 0.1 95.9
CV %: Coefficient of Variation [(SD/mean) × 100]; Accuracy %=[(E−T)/T] × 100; E: Experimentally Determined Concentration; T: Theoretical Concentration
Table 4: Study of the stability method of analysis of salicylic acid in human plasma.
and plasma obtained from a healthy volunteer at 3.5 h after the test 
drug administration (Figure 2C). The retention times for salicylic 
acid-d4 and salicylic acid-d4 were 3.36 ± 0.3 min and 3.32 ± 0.3 min, 
respectively (Figure 2). No endogenous peaks were observed in this area 
of the chromatogram of blank plasma. Thus, for all eight different blank 
plasma samples, the retention time regions were free from endogenous 
interfering peaks. The calibration curves were linear for concentrations 
of 50-4000 ng/mL and the representative regression equation for the 
calibration curves was y=0.000331944x+0.00295049 (r =0.999504). The 
within- and between-run precision and accuracy for the LLOQ and 
QCs are summarized in Table 2. The percentage relative error accuracy 
and the CV obtained in precision studies were lower than 15%, 
insuring the reproducibility and repeatability of the results. The data 
presented in Table 3 indicate no significant matrix effect on ionisation 
of salicylic acid and IS in human plasma (four normal, two lipemic, 
and two hemolysates plasmas). The stability studies did not reveal any 
significant degradation under the conditions of the experiment in the 
short-term stability at room temperature (4 h), freeze-thaw test (three 
cycles) and post processing stability test (24 h), as shown by CV and 
accuracy lower than 15% (Table 4).
The salicylic acid plasma concentration versus time curves 
constructed from analysis of serial plasma samples collected from 
the healthy volunteers (n=15) after oral administration of 81 mg test 
or reference formulation of acetylsalicylic acid are shown in Figure 3 
and the pharmacokinetic parameters of salicylic acid are shown in Table 
5. After oral administration of acetylsalicylic acid, the metabolite salicylic 
acid reached a Cmax of 5433 and 5719 ng/mL in 3.66 and 4.02 h (tmax) for 
the test and for the reference formulation, respectively. The AUC0-∞ values 
were 23800 and 21527 ng.h/mL and the t1/2 was 3.17 and 2.65 h for the 
test and for the reference formulation, respectively. Bae et al. [2] reported 
values of 3780 ng/mL for Cmax, 4.45 h for tmax, 18200 ng.h/mL for AUC0-∞ 
and 2.04 for t1/2 after a single oral dose administration of an enteric-coated 
pellets 100 mg acetylsalicylic acid in healthy volunteers.
The 90% confidence interval (CI 90 %) of the ratios of geometric means 
of Cmax and AUC0-last were completed contained in the interval 80-125% 
(Table 6), established by FDA [17] and ANVISA [18] indicating that the 
new acetylsalicylic acid formulation (test) has a bioavailability equivalent 
to the reference formulation for the rate and the extent of absorption.
Conclusion
Considering that the 90% confidence interval of the geometric 
mean ratios of Cmax and AUC0-last were within the range 80-125%, it 
was concluded that the new formulation (Ecasil-81® coated tablet, 
81 mg acetylsalicylic acid, Biolab Sanus Farmacêutica Ltda.) is 
bioequivalent to the reference formulation (Ecasil-81® coated tablet, 81 
mg acetylsalicylic acid, Biolab Sanus Pharmaceuticals Ltd.) for the rate 
and the extent of absorption. In addition, both formulations were well 
tolerated by the subjects included in this study.
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Parameter Ratio (%) 90% CI Power Intra subject CV (%)
Cmax 95.05 82.02-110.15 0.8105 23.05
AUC0-last 102.91 92.30-114.76 0.9570 16.92
CI (90%): Confidence Interval; CV%: Coefficient of Variation [(SD/mean) × 100]; Cmax: Maximum Plasma Concentration; AUC0-last: Area under the Plasma Concentration 
versus Time Curve Until the Last Concentration Observed
Table 6: Geometric mean ratios of Cmax and AUC0-last, the respective 90% confidence intervals, power and intra subject coefficient of variation of a test and a reference 
formulation of 81 mg coated tablet acetylsalicylic acid.
Figure 3: Plasma concentration versus time curves of salicylic acid in healthy volunteers (n=15) after oral administration of 81 mg dose of a test or reference 
formulation of acetylsalicylic acid. The data are expressed as mean.
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